

Referral Criteria – ISLHD Breast Cancer MDT

	1: For urgent discussion at MDT meeting <i>prior to surgery where possible</i>	2: For discussion at MDT meeting	3: Not for discussion at MDT meeting
New diagnosis	<p>1A: Candidates for neoadjuvant treatment, as defined by one or more of the following:</p> <ul style="list-style-type: none"> • Patient potentially eligible for neoadjuvant clinical trial • Locally advanced disease • Inflammatory breast cancer • Patient preference for breast conservation but borderline suitability at presentation <p>1A: Invasive breast cancer with high likelihood of genetic abnormality (eg early age diagnosis or strong family history)</p> <p>1A: Patients with complex medical histories</p>	<p>2A: Higher risk invasive breast cancer, eg:</p> <ul style="list-style-type: none"> • Larger tumour • High grade • Node positive • Triple negative <p>2A: Complex metastatic breast cancer requiring multidisciplinary input</p> <hr/> <p>2B: Low–moderate risk invasive breast cancer, eg:</p> <ul style="list-style-type: none"> • Smaller tumour • Lower grade • Node negative • Hormone receptor positive / HER2 positive <p>2B: Intermediate and high grade DCIS / LCIS</p>	3A: Low grade DCIS / LCIS
Re-discussion		<p>2C: New issue for patient:</p> <ul style="list-style-type: none"> • previously treated • on treatment 	